Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: What every clinician should know

Annals of Internal Medicine

Volumn 172, Issue 11, 2020, Pages 756-758

  Yazdany, Jinoos ^a   Kim, Alfred H J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZITHROMYCIN; CHLOROQUINE; HYDROXYCHLOROQUINE;

CLINICIAN; CORONAVIRUS DISEASE 2019; HUMAN; INFECTION RISK; INFLUENZA; LUPUS ERYTHEMATOSUS NEPHRITIS; PANDEMIC; RASH; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; BETACORONAVIRUS; CORONAVIRUS INFECTION; DRUG REPOSITIONING; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS PNEUMONIA;

BETACORONAVIRUS; CHLOROQUINE; CORONAVIRUS INFECTIONS; DRUG REPOSITIONING; HUMANS; HYDROXYCHLOROQUINE; PANDEMICS; PNEUMONIA, VIRAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHEUMATIC DISEASES;

EID: 85083655586     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M20-1334     Document Type: Review

References (10)

1. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. [PMID: 32194981] doi:10.1038/s41421 -020-0156-0
2. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. [PMID: 32150618] doi:10.1093/cid/ciaa237
3. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents. 2020:105949. [PMID: 32205204] doi:10.1016/j.ijantimicag.2020.105949
4. Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis. 2011;11:677-683. [PMID: 21550310] doi:10.1016/S1473-3099 (11)70065-2
5. Ooi EE, Chew JS, Loh JP, et al. In vitro inhibition of human influenza A virus replication by chloroquine. Virol J. 2006;3:39. [PMID: 16729896]
6. Kim AHJ, Sparks JA, Liew JW, et al; COVID-19 Global Rheumatology Alliance. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 30 March 2020. [Epub ahead of print]. doi:10.7326/M20-1223
7. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of Zhejiang University (Medical Sciences). 2020;49. doi: 10.3785/j.issn.1008-9292.2020.03.03
8. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150-154. [PMID: 1984192]
9. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:155-166. [PMID: 32034323] doi:10.1038 /s41584-020-0372-x
10. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:3284-3290. [PMID: 17009263]